The Pendulum: The Need to Develop a Safe, Effective, and Equitable Management Strategy for Opioids in Cancer Patients

Danielle Noreika,Margaret Konecny

DOI: https://doi.org/10.2147/rmhp.s455252

2024-04-26

Risk Management and Healthcare Policy

Abstract:Danielle Noreika, Margaret Konecny Department of Risk Management, VCUHealth, Richmond, VA, USA Correspondence: Danielle Noreika, Department of Internal Medicine, VCUHealth, Richmond, VA, USA, Email The opioid epidemic has caused major morbidity and mortality to Americans. Although there are multiple sources of this staggering issue, one inciting factor has been the use of opioids to manage pain. Although recent efforts have changed care pathways for patients with chronic pain, the first-line management of cancer pain remains opioids. Despite this, there is very little evidence and no guidelines/regulations to assist in the management of these patients. Although the literature suggests a number of current barriers to identifying and managing the challenges (such as the preferred management of patients with opioid use disorder (OUD), the optimal approach to taperering, or approaches to disparities), there are no concrete strategies for providers to manage these circumstances. Investing in further research utilizing the national opioid settlement funding, exploring the equity gaps using community based participatory research and community health worker models, and increasing provider education pathways are all potential approaches to improving this issue. These solutions could help identify and address some of the gaps that affect cancer patients taking opioids for pain. Keywords: opioids, cancer pain, disparities, education The current opioid epidemic has caused a resurgent focus on the management of chronic pain. The number of overdose related deaths has reached abysmal new heights in the United States, greater than 106,000 in 2022. 1 Publications such as a 2016 summary in NEJM have noted that a percentage of deaths were presumed related to Opioid Use Disorder (OUD) resulting from pain management with opioids which prompted a vast change to the approach to chronic pain management with limitations in prescribing opioids long-term. 2 CDC guidelines, as well as state regulations (for example, Virginia) 3 exclude cancer patients from their recommendations. Although this allows for individualized treatment planning, it has also led to a lack of standardized approaches to opioid prescribing for cancer patients. It is still recommended that patients with cancer pain are managed with opioids according to the most recent ASCO guidelines. 4 These guidelines do note that there is a paucity of data to guide management of patients with OUD or non-medical opioid use and cancer pain requiring opioids. Furthermore, it has been well noted that there are disparities in pain management due to a variety of factors, and these findings have even been noted in patients who are nearing end of life. 5 A further exploration of the underlying challenges in the management of pain in cancer patients will help define strategies that may improve treatment pathways. Balance is necessary on this topic, as it is also known that there are a number of current barriers that affect the ability of cancer patients to access opioids at times, which may cause inadequate pain treatment. 6 Opioid use disorder that arises in the context of treating cancer pain is unfortunately not well described. A systematic review of chronic pain management studies from 2022 concluded that, although heterogeneity of the studies meant the result of approximately 8% for the prevalence of OUD was inconclusive, the rate of prevalence of the risk of use disorder was 23.5%. 7 In addition to the unknown rates of OUD in cancer patients, little is known on how to manage this circumstance even when diagnosed. Given the lack of evidence to guide therapeutic options, a consensus-based publication for patients with advanced cancer as well as suspicion of opioid misuse or OUD, was developed using a qualitative survey of 120 palliative or addiction medicine specialists. For patients with untreated OUD there was more consensus on an approach using buprenorphine/naloxone whereas there was less certainty on treatment planning for patients with suspected misuse but undiagnosed OUD. 8 Tapering is an expected outcome according to guidelines for patients whose source of pain resolves. If cancer is likely to be cured or treated successfully long-term, the patient should have expectations for an eventual tapering. During the course of the opioid epidemic, tapering became so fraught as patients were abruptly taken off opioids that the FDA released multiple warnings regarding the risks of harm. 9 The CDC has developed materials to guide clinicians on how to manage the tapering process. 10 Many reviews on tapering, even with a focus on palliative or cancer patients, note extrapolation from chronic non-cancer pain. 11 Despite the lack of evidence, there are considerations that -Abstract Truncated-

health care sciences & services,health policy & services